Akari Therapeutics is a biopharmaceutical company focused on developing inhibitors of acute and chronic inflammation, specifically for the treatment of rare and orphan diseases, in particular those where the complement (C5) or leukotriene (LTB4) systems, or both complement and leukotrienes together, play a primary role in disease progression. Akari's lead drug candidate, nomacopan (formerly known as Coversin), is a C5 complement inhibitor that also independently and specifically inhibits leukotriene B4 (LTB4) activity. Nomacopan is currently being clinically evaluated in four areas: bullous pemphigoid (BP), thrombotic microangiopathy (TMA), as well as programs in the eye and lung. The programs in BP and TMA are currently in phase III clinical development.
Company HQ State:
Company HQ Country:
Main Therapeutic Focus:
Lead Product in Development:
nomacopan (formerly known as Coversin)
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):